Summary
This filing is an amendment to a previous 8-K report and serves to clarify Regeneron Pharmaceuticals, Inc.'s decision regarding the frequency of shareholder advisory votes on executive compensation. The company's Board of Directors, accepting the recommendation of its Compensation and Corporate Governance committees, has determined that these advisory votes will continue to be held annually. This decision follows a shareholder vote at the 2023 Annual Meeting of Shareholders held on June 9, 2023, where the option for a one-year frequency received a majority of the votes cast. The amendment, filed on September 7, 2023, with an event date of June 8, 2023, is a procedural update to formally disclose this outcome and the Board's subsequent confirmation.
Key Highlights
- 1Regeneron's Board of Directors will continue to hold annual advisory shareholder votes on executive compensation.
- 2This decision aligns with the majority vote cast by shareholders at the 2023 Annual Meeting.
- 3The shareholder vote on executive compensation frequency took place on June 9, 2023.
- 4The Compensation Committee and Corporate Governance and Compliance Committee recommended maintaining the annual frequency.
- 5This filing is an amendment (8-K/A) to a previous report dated June 14, 2023.
- 6The amendment's purpose is solely to disclose the decision on executive compensation vote frequency.